Glioma
Return to Library
Investigators at Cleveland Clinic publish new data on glioma
2009 AUG 3 - (NewsRx.com) -- According to recent research from the United States, "The value of repealed molecular testing it' patients with multiple resections of gliomas is unclear. The purpose of this study was to assess for evidence of molecular changes for chromosome 1p/19q deletions and epidermal growth factor receptor (EGFR) amplification by fluorescence in situ hybridization in 53 glioma cases in which repeated testing was done." "Paired results for 1p evaluation demonstrated a change in the profile from intact to loss in 1 (2%) of 50 cases: 19q evaluation demonstrated a change in profile in 4 (10%) of 41 cases. There was no change in the EGFR expression in any of the cases tested. There was no change it' the clinical management based on the repeated molecular tests in patients with discrepant repeated results," wrote D. Mahajan and colleagues, Cleveland Clinic. The researchers concluded: "Hence, there seems to be no indication for reflex repeated 1p/19q or EGFR testing in gliomas at the lime of repeated biopsy or resection." Mahajan and colleagues published their study in American Journal of Clinical Pathology (Repeated Molecular Testing in Gliomas A Retrospective Study of 53 Cases. American Journal of Clinical Pathology, 2009;132(1):118-124). For additional information, contact R.A. Prayson, Cleveland Clinic, Dept. of Pathology & Laboratory Medical, L25, 9500 Euclid Avenue, Cleveland, OH 44195, USA. Publisher contact information for the American Journal of Clinical Pathology is: American Society Clinical Pathology, 2100 W Harrison St., Chicago, IL 60612, USA. Keywords: United States, Cleveland, Astrocytoma, Cancer, Clinical Pathology, Glioblastoma, Glioma, Mixed Glioma, Oligodendroglioma, Oncology, Cleveland Clinic. This article was prepared by Pain & Central Nervous System Week editors from staff and other reports. Copyright 2009, Pain & Central Nervous System Week via NewsRx.com.
|
